Boehringer Options Six China Originated Oncology Programs

Company Sino Biopharmaceutical (LaNova Medicines, Beijing Tide); Boehringer Ingelheim Event Type Option-and-license collaboration Modality Antibody-drug conjugates; T-cell engagers Asset Six preclinical programs (undisclosed) Target Undisclosed Disease Area Oncology Summary Sino Biopharmaceutical and Boehringer Ingelheim announced a six-program ADC and T-cell engager option-and-license collaboration on November…